PANAMutyper™ R KRAS

To detect KRAS mutations and determine their response to various treatments in colon cancer.

Cat. No. PNAR-1001

PANAMutyper™ R KRAS

SKU Pcto-0142 Categories , ,

The KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and thyroid cancer. The existence of KRAS mutations is often associated with a prognostic marker of drug response. For example, the KRAS mutation is considered a strong prognostic marker for drug response to tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related to drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) used for colon cancer therapy. Therefore, KRAS mutation testing is necessary to determine drug resistance in patients with colorectal or lung cancer and will be useful for anticancer therapies.

Technical Data

Yes

Marca

Other products

TBE BUFFER TRIS BORATE EDTA
EDTA (ethylenediaminetetraacetic acid) is a chelating agent. In Molecular Biology...
Anaplasma spp. qPCR (AnaSpp 213)
qPCR test for the detection of the genus Anaplasma spp.
PNAClamp™ Mutation Detection Kit EGFR (ver.2)
For detection of EGFR mutations in tissue biopsies - Lung...
qPCR Master Kit v3 (200 rxns)
Part number: 420201
Scroll to Top